Brandywine Realty Trust Prices $400 Million of 8.875% Guaranteed Notes Due 2029
PHILADELPHIA, April 04, 2024 (GLOBE NEWSWIRE) — Brandywine Realty Trust (the “Company”) (NYSE: BDN) announced today that its operating partnership, […]
HII to Host First Quarter Earnings Conference Call and Webcast on May 2
NEWPORT NEWS, Va., April 04, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) will release its first quarter 2024 financial results […]
CTO Realty Growth Announces Pricing of Public Offering of 6.375% Series A Cumulative Redeemable Preferred Stock
WINTER PARK, Fla., April 04, 2024 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (“CTO” or the “Company”) today […]
STMicroelectronics Announces Timing for First Quarter 2024 Earnings Release and Conference Call
STMicroelectronics Announces Timing for First Quarter 2024 Earnings Release and Conference Call Geneva – April 4, 2024 – STMicroelectronics (NYSE: […]
O-I Glass Appoints Gordon Hardie as Chief Executive Officer
Gordon Brings Over 35 Years of Global Leadership Experience Advancing Strategy and Innovation Company Nominates Two New Independent Directors and […]
Six out of 10 Property Managers Experienced Fraud in Past Two Years
CHICAGO, April 04, 2024 (GLOBE NEWSWIRE) — As the rental market grew over the past couple years, fraud naturally followed. […]
XPO Celebrates 30th Anniversary of Its US Trailer Manufacturing Facility
GREENWICH, Conn., April 04, 2024 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, […]
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage […]
Scot Sellers to Be Named Chairman of the Board of Howard Hughes Holdings Inc. at Company’s Upcoming Annual Meeting
Long-time HHH Board Member and former Archstone CEO to succeed Bill Ackman as Board Chairman;Pershing Square Capital Management, L.P. Partner […]
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune […]
